My understanding is that Alchemia is burning $1.6m/quarter excluding optional HyACT development costs. So with $5.5m they can hang on till fondaparinux income and avoid raising money, but only by defering the HA-irinotecan trials another six months.
I'm also skeptical of their ability to get debt funding; if that were relatively easy, why wouldn't they have arranged it already?
My understanding is that Alchemia is burning $1.6m/quarter...
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable